---
schema_version: "secwatch.filing_event.v1"
accession: "0001740797-25-000049"
form_type: "8-K"
ticker: "AVAI"
cik: "0001740797"
company_name: "AVAI BIO, INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:39:49.040542+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avant Technologies forms joint venture Insulinova with Austrianova for diabetes cell therapy

## Summary
- AVAI and Austrianova each hold 50% of Insulinova, a JV for encapsulated insulin cell diabetes treatments.
- AVAI contributes up to $1.5M in capital over 18 months for operations, plus an optional $8.5M loan for clinical testing.
- Austrianova provides exclusive license to its cell encapsulation technology; Kenn Kerr CEO, Walter Günzburg Chairman.
- This agreement supersedes the prior JV from Sept 19, 2025, which included Art-Islets as a party.

## SEC filing metadata
- accession: 0001740797-25-000049
- form_type: 8-K
- ticker: AVAI
- cik: 0001740797
- company_name: AVAI BIO, INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740797/000174079725000049/0001740797-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740797/000174079725000049/avai_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001740797-25-000049
- JSON: https://secwatch.observer/filing/0001740797-25-000049.json
- Plain text: https://secwatch.observer/filing/0001740797-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.